Pazopanib Hydrochloride Patent Expiration
Pazopanib Hydrochloride was first introduced by Novartis Pharmaceuticals Corp
Pazopanib Hydrochloride Patents
Given below is the list of patents protecting Pazopanib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Votrient | US7105530 | Pyrimidineamines as angiogenesis modulators |
Oct 19, 2023
(Expired) | Novartis |
| Votrient | US7262203 | Pyrimidineamines as angiogenesis modulators |
Dec 19, 2021
(Expired) | Novartis |
| Votrient | US8114885 | Chemical compounds |
Dec 19, 2021
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Pazopanib Hydrochloride's patents.
Latest Legal Activities on Pazopanib Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Pazopanib Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical
| 18 Mar, 2024 | US8114885 |
| Maintenance Fee Reminder Mailed Critical
| 02 Oct, 2023 | US8114885 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Aug, 2019 | US8114885 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Feb, 2019 | US7262203 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Mar, 2018 | US7105530 |
| Email Notification Critical
| 05 Jun, 2015 | US8114885 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 05 Jun, 2015 | US8114885 |
| Correspondence Address Change Critical
| 04 Jun, 2015 | US8114885 |
| Email Notification Critical
| 04 Jun, 2015 | US7262203 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 04 Jun, 2015 | US7262203 |
Pazopanib Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pazopanib Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors | National Cancer Institute (NCI) | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | National Cancer Institute (NCI) | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE3 |